Since the combination of EGFR inhibitors and lenvatinib is synergistically lethal to HCC cells, we then tested whether circUCK2(2,3) can affect this synergistic killing effect by treating SNU398 cells with or without circUCK2(2,3) overexpression. This evidence concerns the gene EGFR and hepatocellular carcinoma.